Hyperkalemia
is a condition in which potassium levels in the blood serum are greater than
usual (between 3.5 and 5.0 mmol/L). The kidneys are in charge of maintaining
potassium equilibrium in the body by controlling both its excretion and intake.
When a person's potassium consumption surpasses his or her kidneys' ability to
eliminate it, hyperkalemia develops. The appropriate amount of potassium and
sodium in the body is critical for the myocardium's regular function.
Congestive
heart failure, chronic renal disease, and diabetic kidney disease can all cause
hyperkalemia. When a patient takes renin-angiotensin-aldosterone system
inhibitors (RAAS) for renal illness, the syndrome can develop. Potassium
deficiency can cause irregular heartbeats, which can be fatal.
Hyperkalemia Treatment Market–
Dynamics
During the
projected period, the prevalence of cardiac arrhythmias and chronic renal
disease would be important drivers driving the hyperkalemia therapy market.
Chronic kidney disease affects roughly 30 million people in the United States,
or 15% of the population, according to a research from the Centers for Disease
Control and Prevention (CDC). As the number of people suffering from
lifestyle-related disorders rises, so does the prevalence of hyperkalemia,
which boosts market growth.
Hyperkalemia Treatment Market –
Regional Insights
The global hyperkalemia
treatment market is divided into North America, Latin America, Europe,
Asia Pacific, the Middle East, and Africa based on geography. During the
projected period, North America is expected to dominate the worldwide
hyperkalemia treatment market, followed by Europe.
Because of
advancements in healthcare infrastructure and citizens' unhealthy lifestyles,
the United States enjoys a leading position in the North American market. As
the incidence of hyperkalemia has been observed to range from 2.6 percent to
3.2 percent, this region has the highest rate of hyperkalemia among others.
Furthermore,
due to an increase in drug launches for the treatment of hyperkalemia, the Asia
Pacific hyperkalemia treatment market is predicted to rise significantly. In
May 2018, the United States Food and Drug Administration (US FDA) approved
AstraZeneca's Lokelma, an oral solution of insoluble, non-absorbed sodium
zirconium silicate that serves as a highly-selective potassium-removing agent
for the treatment of hyperkalemia in adults.
Comments
Post a Comment